Related Experiment Videos
Experiences with continuous infusion of recombinant activated factor VII
S Schulman1, R d'Oiron, U Martinowitz
1Department of Medicine, Karolinska Hospital, Stockholm, Sweden. ssc@divmed.ks.se
Summary
Continuous infusion of recombinant activated factor VII (rFVIIa) is effective for hemophilia treatment. Combining rFVIIa with tranexamic acid significantly reduced bleeding complications.
Area of Science:
- Hematology
- Pharmacology
- Clinical Medicine
Background:
- Recombinant activated factor VII (rFVIIa) is a treatment for hemophilia.
- Continuous infusion of rFVIIa is a newer administration method with evolving protocols.
- Optimizing continuous infusion techniques requires further investigation.
Purpose of the Study:
- To collect data on the use of continuous infusion rFVIIa.
- To identify challenges and effective strategies for continuous rFVIIa administration.
- To evaluate factors influencing treatment efficacy and safety.
Main Methods:
- A questionnaire was distributed to 28 hemophilia treatment centers using rFVIIa.
- Data on 40 treatment episodes using continuous infusion rFVIIa were collected from 26 responding centers.
- Treatment parameters, monitoring methods, and complications were analyzed.
Main Results:
- Continuous infusion rFVIIa was used for 40 treatment episodes over 283 days.
- A target factor VII level of 10 IU/ml, monitored by a one-stage clotting assay, was generally adequate.
- Strategies like co-infusion with heparin or saline prevented thrombophlebitis.
- Hemorrhagic complications were reduced when tranexamic acid was used concurrently.
Conclusions:
- Continuous infusion rFVIIa is a viable treatment option for hemophilia.
- Pharmacokinetic evaluation may be important due to variable clearance.
- Further research is needed on optimal monitoring strategies.
- Concurrent use of tranexamic acid enhances safety by reducing bleeding risk.